Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Price: $0.89 +4.71%
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
12 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Needham & Company analyst Chad Messer raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $15.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Needham: 'we think that the event was positive for IMDX'
- Needham Reiterates Buy Rating on DocGo (DCGO)
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
